Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 4/20 | 0.64 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17885845 | 0.86 | ALDH1A1 (0.72) | PLK1KAT2BALDH1A1KMT2ALMNA | |
| SCHEMBL1127285 | 0.85 | PLK1 (0.57) | PLK1KAT2BALDH1A1MAPTKMT2A | |
| SCHEMBL15971141 | 0.84 | NR4A2 (0.72) | KAT2BALDH1A1MAPTKMT2ALMNA | |
| SCHEMBL3043520 | 0.82 | PLK1 (0.62) | PLK1KAT2BALDH1A1MAPTKMT2A | |
| SCHEMBL2429622 | 0.82 | NR4A2 (0.69) | PLK1ALDH1A1MAPTKMT2ALMNA | |
| SCHEMBL30373303 | 0.82 | NR4A2 (0.69) | PLK1ALDH1A1MAPTKMT2ALMNA | |
| SCHEMBL4035309 | 0.81 | ICMT (0.51) | PLK1KAT2BALDH1A1MAPTKMT2A | |
| SCHEMBL3596003 | 0.80 | ICMT (0.46) | PLK1KMT2A | |
| SCHEMBL2644030 | 0.80 | CPT1A (0.44) | PLK1KAT2BMAPT | |
| SCHEMBL5066705 | 0.79 | ALDH1A1 (0.58) | PLK1ALDH1A1MAPTKMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1595866-B1 | Cyanopyrrolidines useful for the treatment of inter alia metabolic syndrome | SANWA KAGAKU KENKYUSHO CO (JP) | 2016-06-08 | — | — | EP | disclosed |
| CN-100434420-C | Compounds that block dipeptidyl peptidase IV | SANWA KAGAKU KENKYUSHO CO (JP) | 2008-11-19 | — | — | CN | disclosed |
| US-7345180-B2 | Compound inhibiting dipeptidyl peptidase IV | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2008-03-18 | — | — | US | disclosed |
| US-20060229286-A1 | Compound inhibiting dipeptidyl peptidase IV | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2006-10-12 | — | — | US | disclosed |
| CN-1745063-A | Compound inhibiting dipeptidyl peptidase iv | SANWA KAGAKU KENKYUSHO CO (JP) | 2006-03-08 | — | — | CN | disclosed |
| EP-1595866-A1 | COMPOUND INHIBITING DIPEPTIDYL PEPTIDASE IV | Sanwa Kagaku Kenkyusho Co., Ltd. (JP) | 2005-11-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229286-A1 | Compound inhibiting dipeptidyl peptidase IV | DPP4, DPP3, DPP7 | PLK1 4524/4885KAT2B 2401/4885ALDH1A1 2457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.